The AML EBMT Cytogenetic Risk Score for Acute Myeloid Leukaemia (AML) Is Prognostic for Outcomes of Allogeneic Stem Cell (HSCT)
Yan Beauverd(St Thomas' Hospital), Yves Chalandon(University of Geneva), Anna D. Petropoulou(University Hospital of Geneva), Maria Mappoura(University Hospital of Geneva), Carmen De Ramón Ortiz(University Hospital of Geneva), Elif Mahne(University Hospital of Geneva), Μaria Anastasiou(National and Kapodistrian University of Athens), Mitja Nabergoj(Platinum Group Coatings (United States)), Laura Bounaix(University Hospital of Geneva), Caroline Stephan(University Hospital of Geneva), Sarah Morin(University Hospital of Geneva), Anne‐Claire Mamez(Délégation Paris 7), Federica Giannotti(Hôpital Saint-Louis), Federico Simonetta(University of Geneva), Thien-An Tran(University Hospital of Geneva), Stavroula Masouridi‐Levrat(University of Geneva), Benjamin Bruno, Christian Ayer(University Hospital of Geneva)
Cited by 0
Related Papers
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
|Journal of Clinical Oncology|2009|562
Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia
|Blood|2015|377
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2016|347